Your browser doesn't support javascript.
The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.
Thomas, Gregory; Frederick, Elizabeth; Hausburg, Melissa; Goldberg, Laura; Hoke, Marshall; Roshon, Michael; Mains, Charles; Bar-Or, David.
  • Thomas G; Ampio Pharmaceuticals, Inc, 373 Inverness Pkwy #200, Englewood, CO 80112 USA.
  • Frederick E; Ampio Pharmaceuticals, Inc, 373 Inverness Pkwy #200, Englewood, CO 80112 USA.
  • Hausburg M; 2Trauma Research Department, Swedish Medical Center, 501 E. Hampden, Englewood, CO 80113 USA.
  • Goldberg L; 3Trauma Research Department, St. Anthony Hospital, 11600 W 2nd Pl, Lakewood, CO 80228 USA.
  • Hoke M; Trauma Research Department, Medical City Plano, 3901 W 15th St, Plano, TX 75075 USA.
  • Roshon M; 5Trauma Research Department, Penrose Hospital, 2222 N Nevada Ave, Colorado Springs, CO 80907 USA.
  • Mains C; 6Trauma Research Department, Research Medical Center, 2316 E Meyer Blvd, Kansas City, MO 64132 USA.
  • Bar-Or D; 7Trauma Research Department, Wesley Medical Center, 550 N Hillside St, Wichita, KS 67214 USA.
Patient Saf Surg ; 14: 21, 2020.
Article in English | MEDLINE | ID: covidwho-245767
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Storm NOS PROCESS_OF Patients
Subject
Storm NOS
Predicate
PROCESS_OF
Object
Patients
3. Lung LOCATION_OF Virus Diseases
Subject
Lung
Predicate
LOCATION_OF
Object
Virus Diseases
4. Virus Diseases COEXISTS_WITH COVID-19
Subject
Virus Diseases
Predicate
COEXISTS_WITH
Object
COVID-19
5. Degenerative polyarthritis AFFECTS Immunoregulation
Subject
Degenerative polyarthritis
Predicate
AFFECTS
Object
Immunoregulation
6. COVID-19 COEXISTS_WITH Storm NOS
Subject
COVID-19
Predicate
COEXISTS_WITH
Object
Storm NOS
7. Storm NOS COEXISTS_WITH COVID-19
Subject
Storm NOS
Predicate
COEXISTS_WITH
Object
COVID-19
8. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
9. Storm NOS PROCESS_OF Patients
Subject
Storm NOS
Predicate
PROCESS_OF
Object
Patients
10. Lung LOCATION_OF Virus Diseases
Subject
Lung
Predicate
LOCATION_OF
Object
Virus Diseases
11. Virus Diseases COEXISTS_WITH COVID-19
Subject
Virus Diseases
Predicate
COEXISTS_WITH
Object
COVID-19
12. Degenerative polyarthritis AFFECTS Immunoregulation
Subject
Degenerative polyarthritis
Predicate
AFFECTS
Object
Immunoregulation
13. COVID-19 COEXISTS_WITH Storm NOS
Subject
COVID-19
Predicate
COEXISTS_WITH
Object
Storm NOS
14. Storm NOS COEXISTS_WITH COVID-19
Subject
Storm NOS
Predicate
COEXISTS_WITH
Object
COVID-19
ABSTRACT

BACKGROUND:

A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a "cytokine storm". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. PRESENTATION OF THE

HYPOTHESIS:

A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. TESTING THE

HYPOTHESIS:

A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. IMPLICATIONS OF

HYPOTHESIS:

If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit.

CONCLUSIONS:

In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Controlled clinical trial / Prognostic study / Randomized controlled trials Language: English Journal: Patient Saf Surg Year: 2020 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Type of study: Controlled clinical trial / Prognostic study / Randomized controlled trials Language: English Journal: Patient Saf Surg Year: 2020 Document Type: Article